RUNX2 and acute myeloid leukemia: To further investigate whether the enhanced receptor interactions could affect anti-leukemia efficacy of GDYO against DNMT3A-mutant AML cells, we compared the anti-leukemia efficacies against OCI-AML3 of bare GDYO, GDYOB and GDYOM in serum-free media (Supplementary Fig. 24a).